Skye Bioscience (SKYE) director Paul A. Grayson receives 75,000 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Skye Bioscience director Paul A. Grayson received a grant of stock options for 75,000 shares of Common Stock. The options have an exercise price of $0.615 per share and expire on March 31, 2036. The award vests in equal monthly installments over one year beginning March 31, 2026, and represents his full reported option holdings from this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Grayson Paul A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	75,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 75,000 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Options granted: 75,000 options Exercise price: $0.615 per share Total options after grant: 75,000 options +3 more

6 metrics

Options granted 75,000 options Stock Option (Right to Buy) covering Common Stock

Exercise price $0.615 per share Exercise price for 75,000-share option grant

Total options after grant 75,000 options Total derivative securities owned following transaction

Expiration date March 31, 2036 Option term end date for the grant

Vesting period start March 31, 2026 Monthly vesting over one year beginning this date

Underlying shares 75,000 shares Common Stock underlying the stock option

Key Terms

Stock Option (Right to Buy), Common Stock, exercise price, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price: "0.6150""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-03-31T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vests in equal monthly installments financial

"The stock option vests in equal monthly installments over the one year period"

Form 4 Insider Transactions: What Each Field Means →

04/02/2026 - 06:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grayson Paul A.

(Last)

(First)

(Middle)

C/O SKYE BIOSCIENCE, INC.

11250 EL CAMINO REAL, SUITE 100

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.615	03/31/2026		A		75,000		⁽¹⁾	03/31/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.

Remarks:

	/s/ Punit S. Dhillon, as Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Skye Bioscience (SKYE) director Paul A. Grayson report in this Form 4?

Paul A. Grayson reported receiving a grant of stock options for 75,000 shares of Skye Bioscience Common Stock. These options give him the right to buy shares at a fixed price, subject to a vesting schedule and expiration date disclosed in the filing.

How many Skye Bioscience (SKYE) stock options were granted to Paul A. Grayson?

Paul A. Grayson was granted stock options covering 75,000 shares of Skye Bioscience Common Stock. This entire 75,000-share amount is shown as his total option holdings following the transaction, indicating the grant created his reported derivative position in this filing.

What is the exercise price of Paul A. Grayson’s Skye Bioscience (SKYE) stock options?

The stock options granted to Paul A. Grayson have an exercise price of $0.615 per share. This means he can purchase Skye Bioscience Common Stock at $0.615 for each share underlying the option, once the options have vested and before they expire.

When do Paul A. Grayson’s Skye Bioscience (SKYE) options vest?

The stock options vest in equal monthly installments over a one-year period beginning March 31, 2026. Each month a portion becomes exercisable, gradually increasing the number of shares he may purchase at the fixed exercise price during the vesting year.

When do the Skye Bioscience (SKYE) stock options granted to Paul A. Grayson expire?

The options granted to Paul A. Grayson expire on March 31, 2036. After that expiration date, any unexercised portion of the 75,000-share award can no longer be used to buy Skye Bioscience Common Stock at the $0.615 exercise price.

Was Paul A. Grayson’s Skye Bioscience (SKYE) Form 4 a market purchase or a compensation grant?

The Form 4 reflects a grant or award acquisition of derivative securities, not an open-market purchase. The transaction code “A” and description indicate a stock option award, with no reported cash purchase of existing shares on the open market.